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1875-9572/Copyright ª 2014, TaiwanAbstract The present article aims to highlight fetal cardiac interventions (FCIs) in terms of in-
dications, strategies, and fetal prognoses. FCIs of the early yearswere predominantly pharmaco-
logical therapies for fetal arrhythmiaor heart block. A transplacental transmissionof therapeutic
agents hasnowbecome themain route ofpharmacological FCIs. Therehavebeenvarious FCI stra-
tegies, which can be categorized into three types: pharmacological, open FCIs, and closed FCIs.
Rather than as a routinemanagement formaterno-fetal cardiac disorders, however, FCIs are only
applied in those fetal cardiac disorders that are at an increased risk of mortality and morbidity
and warrant an interventional therapy. Pharmacological FCIs have been well applied in fetal ar-
rhythmias but require further investigations for novel therapeutic agents. The development of
open FCI in humans is an issue for the long run. Closed FCIs may largely rely on advanced imaging
techniques. Hybrid FCIs might be the future goal in the treatment of fetal heart diseases.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
With the steady development of medical imaging tech-
niques, fetal cardiac interventions (FCIs) have drawn
considerable attention due to the potential merits of pre-
natal diagnosis and successful management of fetal car-
diovascular anomalies, arrhythmias, and heart failure.1
FCIs are carried out to improve fetal cardiac function,
promote fetal intrauterine development and survival, and
enhance postnatal survival.2 Rather than being a routineing Hospital, Fujian Medical
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Pediatric Association. Published bmanagement for materno-fetal cardiac disorders, however,
FCIs are only applied in those fetal cardiac disorders that
have an increased risk of mortality and morbidity and
warrant an interventional therapy.3 There are now various
FCI strategies, which can be categorized into three types:
pharmacological, open FCIs, and closed FCIs. Of these,
closed FCIs can be further subtyped into indirect and direct
closed FCIs. The present article aims to highlight FCIs in
terms of indications, strategies, and fetal prognoses.2. Principles of FCIs
The theoretical principles for FCIs have been described in
guidelines that not only conform to ethics but also take into
account the fetal prognoses and maternal safety (Table 1).y Elsevier Taiwan LLC. All rights reserved.
Table 1 Principles for fetal cardiac interventions.
Fetus ✧ The congenital heart defect may have poor
postnatal therapeutic effect without prenatal
intervention
✧ The intervention may prevent or reduce the
development of the cardiac defect and
improve postnatal prognosis
Mother ✧ Maternal safety must be guaranteed
✧ Maternal fertility must not be affected
Technique ✧ The in-utero intervention is technically
feasible
✧ A multidisciplinary team serves to support
the technical application
Table 2 Inclusion and exclusion criteria of cardiac disor-
ders for fetal cardiac interventions.
Congenital heart defect
Inclusion
Left heart
system
✧ Critical aortic valve stenosis evolving
hypoplastic left heart syndrome
✧ Restrictive atrial level communication
evolving hypoplastic left heart syndrome
✧ Severely stenotic mitral valve
Right heart
system
✧ Pulmonary atresia with intact septal septum
✧ Pulmonary atresia with ventricular septal
defect with hypoplasia of the pulmonary artery
✧ Tetralogy of Fallot with hypoplasia of the
pulmonary artery
Others ✧ Severe type of double outlet right ventricle
✧ Complete transpositions of great vessels with
restrictive atrial level communication
Exclusion
Fetus ✧ Associated with severe malformations of
other organs
✧ Multiple gestations
Mother ✧ Cervical incompetence
✧ Contraindications for the use of narcotics or
uterine contraction inhibitor
82 S.-M. YuanPrenatal intervention is suitable only for a small subset of
fetal conditions, including severe aortic stenosis, pulmo-
nary atresia, and intact atrial septum; therefore interven-
tion should only be offered to candidates fulfilling strict
selection criteria.4 Intrauterine valvuloplasty of a severely
stenotic pulmonary valve or a pulmonary atresia with intact
ventricular septum aims to prevent hypoplasia of the right
ventricle and to enable postnatal biventricular repair.2 The
aim of aortic balloon valvuloplasty for critical aortic ste-
nosis with a small left ventricle or a normal sized left
ventricle but poor function is to increase the chances of
biventricular repair, and to alter the natural history of mid
gestation fetal aortic stenosis toward evolving hypoplastic
left heart syndrome (HLHS).3,5 HLHS often presents in late
gestation, and therefore it cannot be caught in time for
fetal intervention as there would be insufficient time for
fetus in-utero development after intervention.6 Successful
fetal aortic valvuloplasty may result in improvement of in-
utero aortic and mitral valve growth, left ventricular
ejection fraction, bidirectional flow across the foramen,
and antegrade flow in the transverse arch.7 Aortic stenosis
with a high velocity, good ventricular function, and
forward flow in the arch are important preconditions for
fetuses to transit to postnatal treatment. A small ventricle
may suggest non-eligibility for a prenatal procedure.4 The
most important selection criterion for fetuses is critical
aortic valve stenosis evolving HLHS. Other selection
criteria include a left ventricular long-axis Z-score of >3,
retrograde flow in the aortic arch, and left-to-right shunt
across the foramen ovale.8 Under these principles, the in-
clusion criteria (i.e., indications) for the treatment of fetal
cardiac disorders are primarily arterial level and atrial level
abnormalities, whereas the exclusion criteria are predom-
inantly from maternal aspects (Table 2).
3. Pharmacological FCIs
FCIs of the early years are predominantly pharmacological
therapies for fetal arrhythmia or heart block3 to preserve
the intrauterine growth environment with the precondition
of maternal safety, in order to achieve a favorable delivery
in due course after a general evaluation of fetal growth and
development that would thereby facilitate postnatal
treatment.9 At present, transplacental transmission of
therapeutic agents is the main route of pharmacologicalFCIs. Alternative approaches include umbilical vein trans-
mission, fetal intramuscular injection, and fetal intravas-
cular passages. The use of invasive approaches is very
limited in clinical practice, and they were only recom-
mended in those with a very low transplacental passage
rate due to severe hydrops.9 Fetal arrhythmias can be
divided into three types: fetal tachycardia (heart rate >180
beats/minute), bradyarrhythmias (heart rate <110 beats/
minute), and fetal ectopy (irregular rhythm).9
Fetal supraventricular tachycardia is characterized by a
1:1 atrioventricular conduction, usually with a heart rate of
200e300 beats/minute, either paroxysmal or incessant,
and it is associated with fetal hydrops in 36e64%.10 Supra-
ventricular tachycardia is regarded as a cause of nonim-
mune hydrops fetalis with an increased risk of perinatal
mortality.10 Sustained supraventricular tachycardia (>12
hours) and lower gestation showed direct correlations with
hydrops.11 Clinical observations revealed that the gesta-
tional age at delivery was significantly greater in those with
intrauterine management than those without.11 In 1975,
Eibschitz et al12 reported successful intrapartum treatment
by intravenous propranolol for fetal ventricular tachy-
cardia. Atasaral et al10 reported that a fetus developed
tachycardia at a heart rate of 240 beats/minute in the 34th
week of gestation, which was managed with maternal
administration of sotalol 120 mg twice/day on Day 1 of
treatment, then tapered to 80 mg twice/day. The fetal
heart rate dropped to 140 beats/minute and the fetus was
stable until normal vaginal delivery.
The prognosis for fetal atrioventricular heart block
related to congenital heart defects can be extremely poor,
with a combined fetal and neonatal mortality of >80%.
Scheduled early delivery, pacing at a reduced ventricular
rate, and dual-chamber pacing have proved to be
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without SSA/Ro antibody positivity normally has a good
prognosis. Isoimmune atrioventricular block develops as a
result of placental transfer of maternal autoantibodies. The
fetus may develop atrioventricular block in 2% of preg-
nancies with SSA/Ro or SSB/La autoantibodies. Like
hydrops, isoimmune heart block may be associated with
pericardial effusion related to the inflammatory process,
but there are no ascites or pleural effusions. Fetuses with
third-degree atrioventricular block and nonreactive ven-
tricular rates <55 beats/minute are at increased risks of
hydrops fetalis and neonatal heart failure.9
Fetal heart block may result from the myocardial
inflammation and the further fibrosis of the conduct system
due to the deposits of anti-Ro and anti-La antibodies in the
placentas.13,14 Such an immune injury may lead to heart
block at 16the17th week of gestation.15 Fetal bradyar-
rhythmias warrant electrocardiographic monitoring, espe-
cially in the event of long QT intervals.9 When
echocardiography demonstrated a fetal heart rate drop to
<56 beats/minute, maternal administration of oral terbu-
taline 2.5e7.5 mg every 4e6 hour (10e30 mg/day) becomes
necessary. Mothers with fetal isoimmune complete heart
block can take oral dexamethasone (4 mg/day until 30
weeks, and then tapered by 1 mg every other week) from
the date diagnosis was established until the 36th week of
gestation or delivery.16 There is currently no effective in-
trauterine therapy for fetal slow arrhythmias, which are
mainly managed with adrenomimetic drugs and dexa-
methasone. Adrenomimetic drugs, such as salbutamol and
terbutaline, can increase the fetal heart rate by 15e25%
and improve fetal cardiac output. Transplacental dexa-
methasone cannot reverse high-degree heart block, but it
can prevent immune first-degree heart block from devel-
oping into a second- or third-degree condition.15 The use of
antenatal steroid therapy is not widely accepted in the
treatment of fetal immune-mediated heart block owing to
the risks to the fetus. Direct fetal cardiac pacing has rarely
been attempted.14
Hydrops fetalis is an accumulation of fluid or edema in at
least two fetal compartments, including the subcutaneous
tissue, pleura, pericardium, or abdomen.10 Nonimmune
hydrops fetalis may be due to maternal and placental dis-
orders, with common etiologies of cardiovascular abnor-
malities, infectious disease, aneuploidy,17 and critical
aortic valvular stenosis.18 For severe heart failure and
hydrops fetalis, transplacental passage of digoxin is often
declined due to poor outcomes.19 The treatment success
rate with digoxin is about 50% in the presence of hydrops,
which is often associated with poor placental transfer of
digoxin.20 One case of nonimmune fetal hydrops, diagnosed
as mucopolysaccharidosis VII with hypoalbuminemia, was
even subjected to intrauterine albumin transfusions via
cordocentesis on five occasions, but no improvement was
obtained for the hydrops after the albumin transfusions.21
Fetal heart failures were considered a result of neuro-
humoral stimuli and biomechanical stress on car-
diomyocytes, the resultant adverse cardiac pathological
remodeling and pathway activations.22 It has been reported
that digoxin improves fetal cardiac function and maintains
a prolonged and successful gestation for the normal twin.23
For tachyarrhythmia-induced fetal congestive heart failure,the maternal dose of transplacental digoxin is
0.25e0.5 mg/day, whereas for nonimmune hydrops fetalis
caused by supraventricular tachycardia and flutter, the
maternal dose is 0.125e0.5 mg/day.24 Under treatment
with transplacental digoxin with an initial dosage of
0.25 mg/day until delivery, the placental transportation
efficiency (neonate/mother ratio of serum digoxin con-
centration) was 76.45e84.31%, with no postnatal reoccur-
rence of arrhythmias25 A retrospective case series of
fetuses with congestive heart failure were treated with
transplacental digoxin and were evaluated by using a ten-
point cardiovascular profile score (CVPS). The overall
mortality was 32%. A CVPS of 6 was proved to be the best
predictor of survival.26
4. Open FCI
Open FCIs provide insight into the pathophysiology of fetal
cardiacbypass on thebasis ofanimalexperiments. In1986, in-
utero ventricular pacing for complete heart block was
attempted in a human fetus.27 Later, in fetal lambs, pacing
leadswere inserted into the superior vena cavaandascending
aorta through a neck incision by a hysterectomy. The proce-
dure led to a reduced right ventricular output, whereas car-
diac output remained constant when the right atrium was
pacedat 300beats/minute.28 Also in lambs, left ventricular
pacing was later proved to be effective in the treatment of
complete atrioventricular heart block in hydropic fetuses.29
Preliminary researches into fetal cardiac bypass illustrated
thatwithout nitroprusside, placental bloodflowdecreasedby
25e60%, whereas cardiac output increased by 15e25% after
bypass with non-decreasing flows to other fetal organs.
Decreased placental blood flow after bypass was accompa-
nied by a fall in partial pressure of oxygen (PO2) and a rise in
partial pressure of carbon dioxide (PCO2). Nitroprusside
improved placental blood flow, cardiac output, and arterial
blood gases after bypass.30 At normothermia, the placenta
may tolerate a 30-minute umbilical blood flow cessation. As
indomethacin improves placental blood flow after fetal car-
diac bypass, placental perfusion on bypass without indo-
methacin causes severe placental dysfunction. Reddy et al31
compared in-line axial-flow pump and a roller pump with a
venous reservoir for cardiac bypass for 30 minutes in fetal
sheep at 118e122 days of gestation. Three fetuses in the
control group died during the study, whereas all eight fetuses
in the Hemopump group remained stable throughout the
study period. During and after bypass, placental blood flow
was significantly higher, and placental vascular resistance
was significantly lower in the former group than the latter. In
2007, Baker et al32 reported that the addition of calcium
or bicarbonate adversely affected fetal gas exchange during
30-minute bypass in ovine fetuses of 104e110 days of
gestation.
5. Closed FCIs
5.1. Indirect fetal intervention
Kohl33 set two examples of indirect fetal interventions:
fetoscopic laser ablation of the placental vascular
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insertion. It has been recognized that twinetwin transfusion
syndrome (TTTS) can be the underlying cause of fetal car-
diac failure, and twin demise might occur in up to 10% of
monochorionic twin gestations. De Lia et al34 reported that
fetoscopic laser ablation of the placental vascular anoma-
lies resulted in 66.7% survival of the mother and twins. One
(33.3%) patient was complicated by a placental vessel
perforation and developed severe preeclampsia at 29
weeks, necessitating delivery. Fetal cardiac failure associ-
ated with generalized hydrops in untreated fetuses with a
severe bilateral hydrothorax may cause fetal demise.
Ultrasound-guided thoracoamniotic shunt insertion can
decrease the intrathoracic pressure, improve heart func-
tion, and enhance pulmonary re-expansion.35 To improve
fetal heart function, ultrasound-guided fetal pericardial
effusion evacuation can be used as an indirect fetal inter-
vention.36 Laser treatment of the twinetwin communica-
tions or cord ligation with acardiac twins can alleviate fetal
heart failure as well.37Figure 1 Complications of fetal aortic valvuloplasty.395.2. Direct fetal intervention
In 1991, Maxwell et al38 reported aortic valvuloplasty per-
formed in two fetuses with initiated success; however, the
first fetus died 24 hours after the procedure, and the sec-
ond died of renal failure on postnatal Day 28. Later, they
reported another case of fetal aortic valvuloplasty with
longer survival.2 In 2002, Tulzer et al39 performed pulmo-
nary valvuloplasty successfully for critical pulmonary ste-
nosis in two fetuses at 28- and 30-weeks of gestation,
respectively. In 2004, intrauterine atrial septostomy was
attempted by Marshall et al40 in seven fetuses at 26e34
weeks of gestation with HLHS and intact or highly restric-
tive atrial septum. One fetus died, and six remained well
until delivery.
Some patients are diagnosed with aortic valve stenosis
and a normal-sized or dilated left ventricle evolving into
HLHS during the second trimester. Echocardiographic pa-
rameters including retrograde flow in the transverse arch,
severe left ventricular dysfunction, monophasic and short
mitral valve inflow, and left-to-right shunt across the fo-
ramen ovale may predict the development of HLHS. The
potential benefit of fetal cardiac intervention for evolving
HLHS is to decrease the left ventricular afterload and
enhance left heart circulation for the prevention of pro-
gressive left heart dysfunction and hypoplasia.3,5 When
fetal movements have stopped, an 18e19 gauge needle can
be introduced through the maternal abdomen under ultra-
sound guidance and then into the left ventricle through an
intercostal space of the fetal thorax.8 If the fetus has a
complete pulmonary atresia in utero, perforation of the
pulmonary valve by a needle or a radiofrequency wire is
mandatory prior to balloon valvoplasty.4 A few large series
of fetal aortic valvuloplasties for severe aortic stenosis and
evolving HLHS have obtained a technical success of
67e86%,3,8,41 a biventricular repair rate of 24e65%,3,8,41
and a mortality of 13%.8 In a retrospective study, Selamet
Tierney et al7 discovered that mid-gestation fetal balloon
aortic valvuloplasty may effectively improve fetal left
ventricular function. Arzt et al8 performed 24 procedures in23 fetuses with aortic stenosis. The complications included
bradycardia in 39.1% (9/23), left ventricular thrombus in
21.7% (5/23), pericardial effusion > 3 mm in 13% (3/23),
balloon tear off in 8.7% (2/23), and in-utero fetal demise in
13% (3/23) (Figure 1). Bradycardia and/or right ventricular
dysfunction is complicated in 50% of fetal aortic valve in-
terventions.5 Even though biventricular circulation is not
achieved, a functioning left ventricle may support systemic
circulation for further postnatal operations.3
Atrial septostomy for highly restrictive or intact atrial
septum in HLHS may protect the fetuses from pulmonary
vasculature and pulmonary parenchyma damage.42
Ballooning may not be sufficient to keep an atrial level
shunt open for a long time; and atrial septal shunting is thus
an alternative that can be done in early to mid of third
trimester. Fetuses with an atrial level shunting <3 mm may
require urgent atrial septostomy after birth. Intrauterine
atrial septostomy may largely decrease the need for post-
natal interventions. Pulmonary valvuloplasty for pulmonary
atresia with intact ventricular septum and hypoplastic right
ventricles has been reported in the third trimester. Suc-
cessful pulmonary valve perforations render significant
growth of the right ventricle and tricuspid and pulmonary
valve annuli.43
6. Discussion
Transplacental digoxin is the main treatment for fetal heart
failure and fetal hydrops. During the treatment, compre-
hensive evaluation and monitoring of the fetal ventricular
Tei index, CVPS, umbilical arterial pulsatility index and
resistance index are mandatory. Pharmacological FCIs are
primarily the study of fetal pharmacokinetics. Miranda-
Caru´s et al44 created a congenital atrioventricular heart
block model by administering SSA/Ro and SSB/La antibodies
on pregnant murines, laying a foundation for the treatment
of immune fetal atrioventricular heart block, but without
reaching a consensus. In order to observe the trans-
placental transmission rates of flecainide, maternal and
fetal distribution concentrations and elimination rates,
Dimas et al45 conducted a transplacental pharmacokinetic
study of flecainide in the gravid baboon and fetus, and they
provided experimental evidence of safe flecainide use in
clinical practice. To date, there are no animal models of
Fetal cardiac interventions 85fetal rapid arrhythmias and fetal cardiac failure. Clinical
observations have revealed that fetal exposure to chemo-
therapy for maternal cancer in the second or third
trimester of pregnancy does not impair fetal neurological
development or worsen the clinical outcome, indicating a
fetal protective effect from the placental barrier-function
against maternal chemotherapeutic administration during
organogenesis.46 Nevertheless, the use of warfarin in
pregnant patients with a mechanical heart valve prosthesis
can lead to a very different situation. Due to the embry-
opathic effect of warfarin in the first trimester and toxic
effects in the last three weeks of gestation, it is suggested
that subcutaneous heparin administration is substituted for
warfarin during these two periods of gestation.47
The temporary pacemaker implantation accomplished
by Carpenter et al27 in 1986 was the beginning of open FCIs.
The animal experiments thereafter did not achieve any
substantial progression to facilitate clinical fetal pace-
maker implants. Cardiopulmonary bypass as a mandatory
adjunct of fetal cardiac surgery has not been sufficiently
developed, which has restricted advances of fetal cardiac
surgery. A large-scale randomized clinical observation has
revealed that uterine incision is a predictive factor of the
fetal prognosis in open FCIs. The premature delivery rates
were 100%, 80%, and significantly reduced when the uterine
incision was 5 mm, 3.3 mm, and <3.0 mm, respectively.
Open FCI was therefore defined as an operation with a
uterine incision of 3.3 mm including the fetoscopy oper-
ations (the diameter of the 10F sheath used in the fetos-
copy operations was 3.3 mm).48 The influence of the
operation on hemodynamic changes and the pertinent
protective treatment were investigated in fetal lambs un-
dergoing ultrasound-guided intrauterine aortic balloon
valvulotomy. In a fetal lamb model of atrial septal stent
implantation, relations between the shapes of the stents,
the treatment efficacy and endothelialization of the stents
were evaluated by three-dimensional ultrasound. In the
majority of cases (8/10) the procedure was successful
either by piercing the septum primum directly with an 18-
gauge needle or by piercing by an 18-gauge needle inser-
ted through the dilator of a 4F sheath.49
Fetoscopy operations are an open FCI but with minimal
invasion, which makes it appealing for fetal cardiac and
noncardiac interventions, and several series of experi-
mental researches have been conducted on this aspect of
FCIs.50,51 Applications of fetoscopy operations in humans
have been sporadically reported with limited results;
however the risks, especially premature delivery risks
associated with fetoscopy operations, have yet to be
evaluated in detail.52
Closed FCIs are fetal cardiac interventions via a uterine
puncture. An 18e19-gauge puncture needle can meet the
requirement for a fetal cardiac maneuver by maintaining
the integrations of the uterine and the amniotic cavity,
thereby avoiding the risks of premature delivery and
infection from a fetal operation. Currently, closed FCIs
mainly include fetal aortic and pulmonary balloon valvu-
lotomy, and balloon atrial septotomy under the guidance of
ultrasound by way of maternal abdominal wall and uterine
punctures.
FCI is not an independent interventional therapy. In a
minority of cases radical therapeutic outcomes may beattained, but it is a palliative remedy in the majority of the
cases, offering an opportunity for further postnatal treat-
ments, such as aortic and pulmonary balloon valvulotomy,
balloon atrial septotomy, and staged cardiac operations.
The possible cure of fetal cardiac anomalies has to be fully
evaluated prior to FCI. If it is impossible for FCI to be
performed due to the complexity of the fetal cardiac
anomaly, or if there is insufficient time for fetal intra-
uterine development, FCI will not be an effective remedy.
On the contrary, it may bring about ineffective or unfa-
vorable results or even hazards. It is therefore important to
set the inclusion and exclusion criteria in terms of the
timing of FCI and evaluate the predictive risk factors. Both
Z-score and threshold score systems are valuable for the
assessment of prognosis of FCIs in fetuses with a restrictive
atrial communication. They have been proved to directly
correlate with the maximal flow velocity via an atrial shunt,
diameter/area ratio of the atrial shunt, and development
status of cardiac chambers. A CVPS is a reliable indicator
for pre-interventional assessments of fetuses with different
cardiovascular anomalies.1 If the CVPS is 7 points, etio-
logic treatment should be recommended; and if the CVPS is
<5 points, the risks of perinatal mortality could be high.
Successful FCIs could restrain or reverse dysplasia of the
fetal heart and systemic-pulmonary vascular beds. The
procedure, however, may be associated with hemodynamic
instability, which may cause impairment to the fetal brain,
placenta, and other vital organs, and the long-term out-
comes are unknown.
7. Conclusion
FCIs can be associated with potential short-term risks dur-
ing the course of treatment of fetal heart disease, while
the long-term risks warrant further evaluations. It seems
that few pregnant patients may benefit but more may be
subject to risks from FCIs. In selected cases, carefully
weighing the advantages and disadvantages of FCI is of
outstanding importance. Pharmacological FCIs have been
successfully applied in fetal arrhythmias, but further in-
vestigations are required for novel therapeutic agents. The
development of open FCI in humans is an issue for the long
term. Closed FCIs may largely rely on advanced imaging
techniques. Hybrid FCIs may be the future goal in the
treatment of fetal heart diseases.
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